Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Targovax AS (TRVX NO)
Watchlist
10
Analysis
Health Care
•
Norway
Targovax AS develops biopharmaceutics. The Company specializes in creation of therapeutic vaccines for various types of cancer. Targovax serves the healthcare sector.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Targovax AS
•
17 Sep 2020 17:32
•
Issuer-paid
Targovax - Growing list of collaborations and more data in H2
An update from Targovax’s Phase I/II study in unresectable mesothelioma with OCOS-102 was the highlight of Q220 (described in our last note)....
Edison Investment Research
Follow
58 Views
Share
bullish
•
Targovax AS
•
22 Jun 2020 23:14
•
Issuer-paid
Targovax - Confirmatory 12-month mesothelioma update
On 22 June 2020 Targovax reported data from its Phase I/II study in unresectable mesothelioma (a follow up to the first data published in January...
Edison Investment Research
Follow
80 Views
Share
bullish
•
Targovax AS
•
28 May 2020 19:04
•
Issuer-paid
Targovax - ONCOS-102 plus durvalumab trial in spotlight
Targovax has announced that one of the trials with ONCOS-102, which is sponsored by Ludwig Institute for Cancer Research, will be in the spotlight...
Edison Investment Research
Follow
104 Views
Share
bullish
•
Targovax AS
•
23 Mar 2020 19:12
•
Issuer-paid
Targovax - More data in 2020 from both clinical trials
Targovax started 2020 with the first randomised data readout from its Phase I/II trial with oncolytic virus ONCOS-102 in unresectable mesothelioma....
Edison Investment Research
Follow
474 Views
Share
bullish
•
Targovax AS
•
27 Jan 2020 17:57
•
Issuer-paid
Targovax - ONCOS-102 set for late-stage development
Together with the positive Phase I/II mesothelioma trial, Targovax has introduced a preliminary design for its next trial. The new study will...
Edison Investment Research
Follow
716 Views
Share
1
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.44.3
x